Moleculin's Annamycin AML data accepted for presentation at ASH 2026
Interim results from the pivotal MB-108 trial show higher remission rates with Annamycin than placebo, and an independent panel recommended the study continue unchanged.
Moleculin Biotech, Inc. (Nasdaq: MBRX) said on November 4, 2026 that an abstract on its lead drug candidate, Annamycin, has been accepted for presentation at the 2026 American Society of Hematology Annual Meeting, which runs December 12-15, 2026 in New Orleans, Louisiana. The acceptance covers first interim results from a pivotal Phase 2/3 trial that the company said show encouraging remission rates in patients with relapsed or refractory AML.1
The abstract, titled "A Pivotal Phase 2/3 Study of Naxtarubicin as Second Line Therapy in Patients with AML," draws on an initial look at data from the company's MB-108 study, which tests Annamycin alongside cytarabine in relapsed or refractory acute myeloid leukemia patients. In the first 45 randomized patients, complete remission rates reached 43% and 36% in the two Annamycin arms, versus 12% for placebo.1 The company reported no signs, symptoms, or echocardiogram findings pointing to heart toxicity through the data cutoff, consistent with earlier results in Annamycin's development program.1 Full cardiac safety data will still need to go through outside expert and data monitoring committee review ahead of the trial's next interim look. After reviewing the data, the independent Data Monitoring Committee recommended the study continue as designed, keeping all three treatment arms in place.1
The trial, known as MIRACLE (MB-108), is a randomized, double-blind, placebo-controlled study built to confirm earlier Phase 1B/2 results, and the company has said positive results could support a future new drug application, under terms worked out with the FDA. Moleculin has said the trial's second interim analysis is expected in early 2027.1 The poster will be presented by Dr. Oksana Karnabeda of Arensia Exploratory Medicine, LLC. Annamycin, also called naxtarubicin, is also in development for soft tissue sarcoma lung metastases.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.